Shattuck Labs (NASDAQ:STTK) Releases Quarterly Earnings Results

Shattuck Labs (NASDAQ:STTK) released its quarterly earnings results on Thursday. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01, FiscalAI reports. During the same period last year, the business posted ($0.27) EPS.

Shattuck Labs Trading Up 9.4%

STTK stock traded up $0.59 during mid-day trading on Friday, reaching $6.85. The company’s stock had a trading volume of 1,574,131 shares, compared to its average volume of 448,215. The stock has a market cap of $517.72 million, a PE ratio of -10.87 and a beta of 1.18. The company’s 50 day moving average is $6.34 and its two-hundred day moving average is $4.29. Shattuck Labs has a fifty-two week low of $0.71 and a fifty-two week high of $8.33.

Hedge Funds Weigh In On Shattuck Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new position in shares of Shattuck Labs during the 3rd quarter valued at about $38,000. Squarepoint Ops LLC acquired a new stake in Shattuck Labs during the third quarter worth about $46,000. Dimensional Fund Advisors LP acquired a new stake in Shattuck Labs during the fourth quarter worth about $85,000. OMERS ADMINISTRATION Corp purchased a new position in Shattuck Labs during the fourth quarter worth about $97,000. Finally, Invesco Ltd. acquired a new position in Shattuck Labs in the 4th quarter valued at about $103,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on STTK shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd. Cantor Fitzgerald assumed coverage on shares of Shattuck Labs in a research note on Monday, April 27th. They issued an “overweight” rating for the company. Piper Sandler started coverage on Shattuck Labs in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $15.00 price target on the stock. Needham & Company LLC started coverage on Shattuck Labs in a report on Friday, March 6th. They set a “buy” rating and a $25.00 price objective for the company. Finally, TD Cowen reaffirmed a “buy” rating on shares of Shattuck Labs in a research report on Friday, March 6th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.